- Home
- ADVM vs APLT Comparison
ADVM vs APLT Comparison
Compare ADVM & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- APLT
- Stock Information
- Founded
- ADVM 2006
- APLT 2016
- Country
- ADVM United States
- APLT United States
- Employees
- ADVM N/A
- APLT N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- APLT Health Care
- Exchange
- ADVM Nasdaq
- APLT Nasdaq
- Market Cap
- ADVM 66.3M
- APLT 63.6M
- IPO Year
- ADVM 2014
- APLT 2019
- Fundamental
- Price
- ADVM $3.02
- APLT $0.42
- Analyst Decision
- ADVM Strong Buy
- APLT Buy
- Analyst Count
- ADVM 4
- APLT 6
- Target Price
- ADVM $19.75
- APLT $6.10
- AVG Volume (30 Days)
- ADVM 84.1K
- APLT 883.6K
- Earning Date
- ADVM 11-03-2025
- APLT 11-06-2025
- Dividend Yield
- ADVM N/A
- APLT N/A
- EPS Growth
- ADVM N/A
- APLT N/A
- EPS
- ADVM N/A
- APLT N/A
- Revenue
- ADVM $1,000,000.00
- APLT $121,000.00
- Revenue This Year
- ADVM $1,836.70
- APLT N/A
- Revenue Next Year
- ADVM N/A
- APLT $5,931.24
- P/E Ratio
- ADVM N/A
- APLT N/A
- Revenue Growth
- ADVM N/A
- APLT N/A
- 52 Week Low
- ADVM $1.78
- APLT $0.30
- 52 Week High
- ADVM $8.56
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ADVM 50.02
- APLT 38.92
- Support Level
- ADVM $2.93
- APLT $0.43
- Resistance Level
- ADVM $3.59
- APLT $0.46
- Average True Range (ATR)
- ADVM 0.22
- APLT 0.03
- MACD
- ADVM -0.02
- APLT -0.01
- Stochastic Oscillator
- ADVM 13.64
- APLT 0.35
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.